Patents by Inventor Walter Cabri

Walter Cabri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220041680
    Abstract: The present invention provides a process for the manufacture of GLP-1 analogues with high yield and purity by fragment condensation on the solid phase. In particular, it describes a convergent synthesis by condensation of a C-terminal pseudoproline fragment A with a fragment B bound to a solid support, followed by deprotection and cleavage from the support and final purification to yield the desired peptide. The invention further provides intermediates useful in the manufacturing process.
    Type: Application
    Filed: October 9, 2019
    Publication date: February 10, 2022
    Applicant: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Giuseppina Maria INCISIVO, Andrea ORLANDIN, Antonio RICCI, Ivan GURYANOV, Walter CABRI
  • Publication number: 20220033443
    Abstract: The present invention provides a manufacturing process for preparing a peptide, preferably a decapeptide, such as degarelix, by incorporating p-nitro-phenylalanin in the amino acid sequence preferably during stepwise solid phase synthesis, and converting these into the required amino acids Aph(Hor) and/or D-Aph(Cbm), preferably while attached to a solid phase. The invention further provides intermediates useful in the manufacturing process.
    Type: Application
    Filed: October 15, 2021
    Publication date: February 3, 2022
    Applicant: Fresenius Kabi iPSUM S.r.l
    Inventors: Antonio RICCI, Jacopo ZANON, Walter CABRI, Ivan GURYANOV, Andrea ORLANDIN, Barbara BIONDI, Fernando FORMAGGIO, Dario VISENTINI
  • Publication number: 20220009917
    Abstract: The present invention relates to a process for preparing alectinib, or a pharmaceutically acceptable salt thereof, and to related intermediates.
    Type: Application
    Filed: May 24, 2021
    Publication date: January 13, 2022
    Applicants: FRESENIUS KABI IPSUM S.R.L., Alma Mater Studiorum - Università di Bologna
    Inventors: Walter CABRI, Alessandra TOLOMELLI, Assunta DE NISI, Lucia FERRAZZANO
  • Publication number: 20210371410
    Abstract: The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.
    Type: Application
    Filed: August 16, 2021
    Publication date: December 2, 2021
    Applicant: FRESENIUS KABI ONCOLOGY LIMITED
    Inventors: Vinod Singh TOMAR, Abul AZIM, Nitin GUPTA, Saswata LAHIRI, Walter CABRI
  • Patent number: 11168114
    Abstract: The present invention provides a manufacturing process for preparing a peptide, preferably a decapeptide, such as degarelix, by incorporating p-nitro-phenylalanin in the amino acid sequence preferably during stepwise solid phase synthesis, and converting these into the required amino acids Aph(Hor) and/or D-Aph(Cbm), preferably while attached to a solid phase. The invention further provides intermediates useful in the manufacturing process.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: November 9, 2021
    Assignee: FRESENIUS KABI IPSUM S.R.L
    Inventors: Antonio Ricci, Jacopo Zanon, Walter Cabri, Ivan Guryanov, Andrea Orlandin, Barbara Biondi, Fernando Formaggio, Dario Visentini
  • Publication number: 20210292276
    Abstract: The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.
    Type: Application
    Filed: June 3, 2021
    Publication date: September 23, 2021
    Applicant: FRESENIUS KABI ONCOLOGY LTD.
    Inventors: Sridhar Reddy MALE, Saurabh UPADHYAY, Suneel Kumar SHARMA, Hrishikesh ACHARYA, Govind SINGH, Saswata LAHIRI, Walter CABRI
  • Patent number: 11098037
    Abstract: The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.
    Type: Grant
    Filed: July 4, 2018
    Date of Patent: August 24, 2021
    Assignee: Fresenius Kabi Oncology Ltd.
    Inventors: Vinod Singh Tomar, Abul Azim, Nitin Gupta, Saswata Lahiri, Walter Cabri
  • Publication number: 20210238230
    Abstract: The present invention provides a process for the manufacture of peptidomimetic drug icatibant with high yield and purity by fragment condensation on the solid phase. In particular, it describes a convergent synthesis by condensation of a protected C-terminal fragment bound to a solid support and a protected N-terminal fragment, followed by cleavage from the support and resulting in a crude peptide of high purity, which is further purified to obtain pure icatibant in high yield. The invention further provides intermediates useful in the manufacturing process.
    Type: Application
    Filed: April 18, 2019
    Publication date: August 5, 2021
    Applicant: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Walter CABRI, Alice POZZEBON, Angelo VIOLA, Antonio RICCI, Andrea BORGOGNO, Ivan GURYANOV
  • Patent number: 11078231
    Abstract: The present invention relates to a process for the purification of compound of formula II, wherein X may be independently selected from trifluoroacetic acid, hydrochloric acid, hydrobromic acid, p-toluene sulfonic acid and phosphoric acid; its isolation as solid and use for the preparation of carfilzomib.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: August 3, 2021
    Assignee: FRESENIUS KABI ONCOLOGY LTD
    Inventors: Walter Cabri, Saswata Lahiri, Govind Singh, Sarbjot Singh Sokhi, Maneesh Kumar Pandey, Raj Narayan Tiwari, Sonu Prasad Shukla
  • Patent number: 11059777
    Abstract: The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: July 13, 2021
    Assignee: Fresenius Kabi Oncology Ltd.
    Inventors: Sridhar Reddy Male, Saurabh Upadhyay, Suneel Kumar Sharma, Hrishikesh Acharya, Govind Singh, Saswata Lahiri, Walter Cabri
  • Patent number: 11014919
    Abstract: The present invention relates to a process for preparing alectinib, or a pharmaceutically acceptable salt thereof, and to related intermediates.
    Type: Grant
    Filed: December 6, 2019
    Date of Patent: May 25, 2021
    Assignees: Fresenius Kabi IPSUM S.r.l., Alma Mater Studiorum—Università di Bologna
    Inventors: Walter Cabri, Alessandra Tolomelli, Assunta De Nisi, Lucia Ferrazzano
  • Publication number: 20210024506
    Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.
    Type: Application
    Filed: October 1, 2020
    Publication date: January 28, 2021
    Applicant: FRESENIUS KABI ONCOLOGY LIMITED
    Inventors: Walter CABRI, Saswata LAHIRI, Bhuwan Bhaskar MISHRA, Abul AZIM, Nilendu PANDA, Poli Reddy BHAVANAM, Krishanu RAY, Nikunj KACHHADIA, Kumber SINGH
  • Publication number: 20200399339
    Abstract: The present invention provides an improved process for the preparation of high purity glucagon comprising the use of Xmb-protected amino acids, wherein may Xmb include, e.g., 2,4,6-trimethoxybenzyl, 2,4-dimethoxybenzyl, or 2-hydroxy-4-methoxybenzyl. The process also comprises the use of building blocks such as pseudoprolines to avoid aggregation and obtain the product in high yield and purity.
    Type: Application
    Filed: June 18, 2020
    Publication date: December 24, 2020
    Applicant: FRESENIUS KABI IPSUM S.R.L.
    Inventors: Andrea ORLANDIN, Antonio RICCI, Walter CABRI, Steve MCINTYRE, Alex SAUNDERS
  • Patent number: 10800763
    Abstract: The present invention relates to crystalline forms of Afatinib and its dimaleate salt. The present invention also relates to processes for the preparation of crystalline forms of Afatinib and its dimaleate salt. The present invention further relates to pharmaceutical compositions of such crystalline forms of Afatinib dimaleate and use thereof in the treatment of a patient in need thereof.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: October 13, 2020
    Assignee: Fresenius Kabi Oncology Ltd.
    Inventors: Walter Cabri, Saswata Lahiri, Bhuwan Bhaskar Mishra, Abul Azim, Nilendu Panda, Poli Reddy Bhavanam, Krishanu Ray, Nikunj Kachhadia, Kumber Singh
  • Publication number: 20200277295
    Abstract: The invention relates to a process for the preparation of ribociclib of formula V or its salts. The invention provides novel crystalline forms of ribociclib succinate and ribociclib trifluoroacetate. The present invention also relates to pharmaceutical compositions comprising a crystalline form of ribociclib succinate and at least a pharmaceutically acceptable carrier. It further relates to the use of such compositions in the treatment of cancer.
    Type: Application
    Filed: October 26, 2018
    Publication date: September 3, 2020
    Applicant: FRESENIUS KABI ONCOLOGY LIMITED
    Inventors: Sarbjot Singh SOKHI, Govind SINGH, Saswata LAHIRI, Maneesh Kumar PANDEY, Raj Narayan TIWARI, Sonu SHUKLA, Sachin MUSMADE, Heena DUA, Walter CABRI
  • Publication number: 20200181133
    Abstract: The present invention relates to a process for preparing alectinib, or a pharmaceutically acceptable salt thereof, and to related intermediates.
    Type: Application
    Filed: December 6, 2019
    Publication date: June 11, 2020
    Applicants: FRESENIUS KABI IPSUM S.R.L., Alma Mater Studiorum - Università di Bologna
    Inventors: Walter CABRI, Alessandra TOLOMELLI, Assunta DE NISI, Lucia FERRAZZANO
  • Publication number: 20200172577
    Abstract: The present invention provides a manufacturing process for preparing a peptide, preferably a decapeptide, such as degarelix, by incorporating p-nitro-phenylalanin in the amino acid sequence preferably during stepwise solid phase synthesis, and converting these into the required amino acids Aph(Hor) and/or D-Aph(Cbm), preferably while attached to a solid phase. The invention further provides intermediates useful in the manufacturing process.
    Type: Application
    Filed: December 19, 2016
    Publication date: June 4, 2020
    Inventors: Antonio RICCI, Jacopo ZANON, Walter CABRI, Ivan GURYANOV, Andrea ORLANDIN, Barbara BIONDI, Fernando FORMAGGIO, Dario VISENTINI
  • Publication number: 20200140427
    Abstract: The present invention relates to a process for preparing the Alectinib or a pharmaceutically acceptable salt thereof using lesser reaction steps and also eliminating expensive and time-consuming column chromatography. The invention also relates to novel polymorphic forms of Alectinib and Alectinib hydrochloride.
    Type: Application
    Filed: July 4, 2018
    Publication date: May 7, 2020
    Applicant: FRESENIUS KABI ONCOLOGY LIMITED
    Inventors: Vinod Singh TOMAR, Abul AZIM, Nitin GUPTA, Saswata LAHIRI, Walter CABRI
  • Patent number: 10577433
    Abstract: The present application provides an improved process for the preparation of sugammadex by reacting a salt of 3-mercapto propionic acid with 6-per-deoxy-6-per-halo-?-cyclodextrin in a suitable organic solvent. This application also provides crystalline form of a salt of 3-mercapto propionic acid, preferably di sodium salt of 3-mercapto propionic acid and its use for the preparation of sugammadex, whereas formula (I) shows the sodium salt of sugammadex.
    Type: Grant
    Filed: March 20, 2017
    Date of Patent: March 3, 2020
    Assignee: Fresenius Kabi iPSUM S.r.l.
    Inventors: Walter Cabri, Antonio Ricci, Jacopo Zanon, Saswata Lahiri, Govind Singh, Shivaji Haribhau Shelke, Tapanjyoti Biswal, Nitin Kumar, Madan Singh
  • Publication number: 20200031850
    Abstract: The present invention relates to an improved process for the preparation of a compound of formula (I), wherein PG1 may be independently selected from tert-butyloxycarbonyl (Boc), phthaloyl, 9-fluorenylmethyloxycarbonyl (Fmoc), triphenylmethyl (Trityl), carboxybenzyl (Cbz), trifluoroacetyl, benzyl (Bn), benzylidene, methanesulfonyl (Mesyl), toluene sulfonyl (Tosyl) or acyl; its isolation as solid and use for the preparation of the compound of formula (IV), in particular the compound of formula (IV) i.e. [(1R)-3-methyl-1[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid with more than 99.95% chiral purity, as measured by HPLC.
    Type: Application
    Filed: February 19, 2018
    Publication date: January 30, 2020
    Applicant: FRESENIUS KABI ONCOLOGY LIMITED
    Inventors: Maneesh Kumar PANDEY, Raj Narayan TIWARI, Sonu SHUKLA, Sarbjot Singh SOKHI, Govind SINGH, Saswata LAHIRI, Walter CABRI